On May 16, 2018, Mylan N.V. and Mylan Inc., an indirect wholly owned subsidiary of Mylan N.V., delivered notices to The Bank of New York Mellon, as trustee (the “Trustee”), notifying the Trustee of their election to redeem the following series of notes on June 15, 2018 (the “Redemption Date”):
Collaboration aims to demystify STEM and broaden its perceived application Program will leverage 4-H infrastructure and WVU STEM outreach, reaching every county in West Virginia Mylan commits a $5 million charitable contribution over 10 years to empower West Virginia children to be Curious, Active,
On May 9, 2018, the U.S. Food and Drug Administration (FDA) posted a supply notification about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, on its website to provide greater
HERTFORDSHIRE , England and PITTSBURGH , May 9, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three months ended March 31, 2018. First Quarter 2018 Financial Highlights Total revenues of $2.68 billion , down 1% compared to the prior year period.
HERTFORDSHIRE, England and PITTSBURGH , May 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its first quarter 2018 financial results, on Wed., May 9 , before the open of the U.S. financial markets. The company also will host a
HERTFORDSHIRE, England and PITTSBURGH , April 25, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz ® Tablets.
Three posters highlight Mylan's rigorous Glatiramer Acetate development program HERTFORDSHIRE, England , and PITTSBURGH , April 21, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program
Although it’s Mylan’s policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue.
Management details progress on complex scientific programs and commercial diversification; reaffirms 2018 guidance Company is built to last and positioned for growth HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
Mylan acquires global development and marketing rights from Prayog Labs Once approved, the product could potentially offer a fast-acting, non-addictive treatment for acute pain HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.